SEC Comment Letter 0000000000-26-007819 to Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc.
Date: Aug. 10, 2026 · CIK: 0001506251 · Accession: 0000000000-26-007819
AI Filing Summary & Sentiment
Reasoning
Letter
May 28, 2026
Jaime Bartushak Chief Financial Officer Citius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, New Jersey 07016 Re: Citius Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 22, 2026 File No. 333- 296195 Dear Jaime Bartushak: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
cc: Lorna A. Knick, Esq. Division of Corporation Finance
Office of Life Sciences
Show Raw Text
May 28, 2026 Jaime Bartushak Chief Financial Officer Citius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, New Jersey 07016 Re: Citius Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 22, 2026 File No. 333- 296195 Dear Jaime Bartushak: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, cc: Lorna A. Knick, Esq. Division of Corporation Finance Office of Life Sciences